g casino jobs
Pep Guardiola has hit back at suggestions he is not selecting because of a rift with the midfielder. De Bruyne has been restricted to five substitute appearances since returning from an abdominal injury suffered against in September. Guardiola waited until City were against on Sunday before introducing the 33-year-old from the bench. It prompted Sky Sports pundits Gary Neville and Jamie Carragher to speculate that there is a simmering problem between the player and manager. Neville said the situation with De Bruyne is "unusual, bizarre, strange" and that "something is definitely going on in the dressing room." It was a view backed up by Carrager, who said "something is going on with De Bruyne" and "something isn't right if he isn't in the team when he is fit." In a news conference on Tuesday, Guardiola was not asked directly about the situation with De Bruyne. Instead, he addressed it unprompted. "People say I've got a problem with Kevin," Guardiola said. "Do you think I like to not play with Kevin? No, I don't want Kevin to play. The guy who has the most talent in the final third. I don't want it. I have a personal problem with him after nine years together. "He's delivered to me the biggest success to this club. But he's been five months injured and two months injured. He's 33-years-old. "He needs time to find his best. Like last season, step by step. He'll try to do it and feel better. I'm desperate to have his best." Guardiola hinted De Bruyne could return to the team when they next play -- against in the on Wednesday -- after he played the final 12 minutes at Anfield. City are hoping to end a run of seven games without a win when they line up against Nuno Espírito Santo's side, who sit sixth in the Premier League table. Four consecutive league defeats has seen City slip to fifth. While Guardiola is keen to have De Bruyne back, he is warned that the international will "not solve our problems." "I'd love to have the Kevin in his prime -- 26 or 27," Guardiola said. "He would love it too. But he is not 26 or 27 anymore. He had injuries in the past, important and long ones. He is a guy who needs to be physically fit for his space and energy. "He played in 10 or 11 seasons a lot of games. I know he is desperate to help us, he gives glimpses of brilliance that only he can have. "But always I said, he himself will not solve our problems. Like Erling [Haaland] won't solve it himself. We attack and defend together. We want the best players back. Hopefully step by step the confidence will come back and we'll get the best of all of us."
AP Trending SummaryBrief at 6:46 p.m. EST
VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “ Company ”, “ Rakovina ”, or “ Rakovina Therapeutics ”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the closing of a $3.0 million private placement. The private placement consists of 50,000,000 units (the “ Units ”) at a price of $0.06 per Unit. Each Unit consists of one common share of the Company (each, a “ Common Share ”) and one Common Share purchase warrant (each, a “ Warrant ”). Each Warrant entitles the holder thereof to subscribe for and purchase one Common Share of the Company for a period of 24 months from the date of issue at a price of $0.10 per Common Share. Rakovina retains the right to accelerate the Warrant exercise period if, upon written notice to the holder, the 20-day volume-weighted average price of its Common Shares exceeds $0.30. In connection with the Private Placement, the Company paid cash finder’s fees to Canaccord Genuity Corp., Ventum Financial Corp., Haywood Securities Inc., Research Capital Corporation, Hampton Securities Limited, Ewing Morris & Co. Investment Partners Ltd. and Leede Financial Inc. (each a “ Finder ”, and collectively, the “ Finders ”) in the aggregate amount of $180,841 and issued a total of 3,021,872 non-transferable finder’s warrants (each, a “ Finder’s Warrant ’) to the Finders, in accordance with the policies of the TSX Venture Exchange (the “ TSXV ”). Each Finder’s Warrant entitles the holder thereof to subscribe for and purchase one Common share of the Company for a period of 24 months from the date of issue at a price of $0.10 per Common Share, subject to acceleration on the same terms as the Warrants issued in connection with the private placement. The private placement is subject to the final acceptance of the TSXV and all securities issuable in connection with the private placement are subject to a hold period of four months plus one day from the date of issuance, in accordance with applicable securities laws. The proceeds of the private placement will be used to accelerate both discovery and development of the Company’s proprietary drug candidates, shortlisted from the Deep Docking and Variational AI platforms. “This overwhelming response from our investors underscores the strength of our science, the extraordinary talent and dedication of our team and the transformative potential of our therapies,” said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. “We are deeply grateful for the trust placed in us and remain resolute in our mission to utilize leading AI technologies to develop innovative solutions for cancer care.” The Company extends its heartfelt thanks to its investors, partners, and team for their unwavering support as Rakovina continues its work to bring new hope to patients and families affected by cancer. Rakovina is pleased to announce its engagement of Fairfax Partners Inc. as its Investor Relations (IR) partner. With extensive expertise in investor engagement strategies, Fairfax will implement a comprehensive six-month IR program designed to enhance Rakovina’s market presence and expand its investor base. The program, which includes an option to renew for an additional six months, focuses on complementing traditional IR efforts with targeted online marketing campaigns, activation of a robust social media influencer network, and collaboration with external consultants and global wealth management channels. These initiatives will support Rakovina’s strategic plan for 2025 by institutionalizing its investor base and strengthening its distribution capabilities. Under the agreement, Fairfax will receive a monthly fee of $5,000 plus GST, a one-time setup fee of $15,000 plus GST, and a marketing budget of $120,000 plus GST, disbursed as follows: $80,000 upon signing and $40,000 two months later. Services provided by Fairfax include inbound and outbound phone communications, website and social media management, marketing material preparation, news release support, and roadshow assistance, ensuring Rakovina’s IR efforts align with market expectations. Fairfax Partners Inc., located at 306-1238 Seymour Street, Vancouver, BC, confirms that neither its directors nor officers hold any securities of Rakovina. For inquiries, please contact connect@fairfaxpartners.com. “We are thrilled to partner with the seasoned team at Fairfax Partners to expand our investor base and increase awareness of Rakovina Therapeutics’ vision. Fairfax’s creative and forward-thinking approach to investor relations will be a critical asset as we enter a pivotal year. By harnessing their extensive network and digital expertise, we aim to significantly enhance our market presence and deliver lasting value to our shareholders,” said Mr. Bacha. About Rakovina Therapeutics Inc. Rakovina Therapeutics Inc. is dedicated to developing innovative cancer therapies targeting the DNA-damage response. The company has established a development pipeline of novel DNA-damage response inhibitors by leveraging Artificial Intelligence (AI) to accelerate the identification and optimization of drug candidates. Rakovina Therapeutics aims to advance one or more of these candidates into human clinical trials in collaboration with pharmaceutical partners and secure marketing approvals from Health Canada, the U.S. Food and Drug Administration, and other international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com . The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Forward-Looking Statements: This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the terms of the private placement, the closing of the private placement, the receipt of final TSXV approval, the proposed business plan of the Company; the Company’s commitment to advancing new cancer therapies; the ability of the Company to extract value from its AI collaborations; the Company’s ability to execute on its business plans while maintaining high standards of research; the ability of Pharma Inventor Inc. to accurately provide medicinal chemistry support; the projected timeline and effectiveness of the Company’s strategy to utilize the Deep Docking AI platform; and the Company’s ability to generate shareholder value. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at www.sedar.com. For Further Information Contact: David Hyman, Chief Financial Officer info@rakovinatherapeutics.com Invest Relations &Media Michelle Seltenrich ir@rakovinatherapeutics.com 778-773-5432
Colorado star Travis Hunter says Coach Prime `ain’t going nowhere'Is Enron back? If it’s a joke, some former employees aren’t laughingIn a recent interview, NVIDIA Corporation NVDA CEO Jensen Huang shared his thoughts on the company's focus on supply as demand remains "incredible," a development that was a big topic in the company's recent financial results. What Happened: Although Nvidia stock has dipped since its third-quarter results, analysts remain unfazed , pointing to surging demand for Blackwell chips. During an appearance on Fox Business Network's "The Claman Countdown," Huang was asked about the problem many CEOs would love to have of demand being greater than supply. "Hopper and Blackwell are two just magnificent computing systems," Huang said . Huang said demand is strong for data centers to get their hands on Blackwell chips. "We're going to go from zero billion dollars of Blackwell to many billions of dollars of Blackwell. And so, it's going to be an incredible thing. But the demand is just incredible." During the interview, Huang was asked about the large number of customers and big-name customers who have placed orders and the process for determining which customers get their Blackwell chips first. "We try to be fair with everyone so that they can all get their AI infrastructure up and running. We also make sure that their infrastructure is ready. And so, between us and them, there's no sense shipping computers if the data center and the power and the readiness of the system is not there," Huang said. Huang highlighted Alphabet, Dell and CoreWeave as companies who have expressed their optimism. "Everybody's really proud of the system they've stood up and we're all just racing to get there." Huang said Nvidia does pricing "based on the value delivered." "In a lot of ways, it's kind of like generating electricity in the last industrial revolution, and there are all this machinery, these large machinery called A.C. generators, and they produce electricity. We're now producing this miracle called artificial intelligence." Are you buying when the CEOs of the Magnificent 7 are selling? Stay in the know with our Insider Trades page — see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares. What's Next: Huang said the company is "in good shape" and confident in its Blackwell production ramp. "Our demand is greater than our supply. And so, we need to get more out," Huang said. Huang said Nvidia is working with thousands of AI native companies and it's hard to have infrastructure available for all of them. "We're working super hard to get there as fast as we can, which is the reason why we're ramping Blackwell so hard." Nvidia's success comes largely in the United States, Huang added. The CEO sees an opportunity to continue to expand to other countries. "Over time and very quickly, whether it's in the west or in the east, we're going to see just about every single country jumping onto this A.I. revolution, this age of A.I." Huang brushed off concerns that AI will take over the world and take all the jobs. "AI can do a lot of tasks, but they can't do 100% of our jobs. That's the big idea." Huang said AI is going to revolutionize and transform jobs and it's important that people learn how to use AI. "What is very likely is that AI will do 20, 30, 40% of 100% of the jobs in the world." NVDA Price Action: Nvidia stock is down 3% to $142.10 on Friday versus a 52-week trading range of $45.01 to $152.89. Nvidia stock is up 195% year-to-date, but has fallen 1% over the last month. Read Next: Nvidia CEO Jensen Huang Doesn’t Wear A Watch After A Gardner Taught Him The Secret Of Time Image created with photos from Nivida and Shutterstock. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Orca seen wearing a salmon hat for first time since 1980s. Why do they do it?Jack Butland backs Rangers star to shine against Celtic in Hampden final after lighting up Europa League